Particle Health vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Particle Health provides a health data exchange API enabling healthcare apps to access longitudinal patient records from national networks with a single integration.
About
Particle Health is a health data exchange company founded in 2018 that provides developers and healthcare companies with a single API to access patient clinical records from national health information networks including CommonWell, Carequality, and others. The company abstracts the complexity of connecting to dozens of regional health information exchanges and national networks behind a simple developer-friendly API, enabling healthcare applications to retrieve longitudinal patient records including medical history, lab results, diagnoses, and medications from any participating provider. Particle raised $60M and serves digital health companies, telehealth platforms, health plans, and healthcare analytics firms that need access to real-world patient data to power clinical decision support, care management, and value-based care programs. The company provides HIPAA-compliant data access with identity verification and purpose-of-treatment validation to ensure appropriate use of patient records. Particle's API approach reduces the time and cost for healthcare companies to build clinical data infrastructure from months of complex integrations to days of API implementation.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.